The test, which uses automated reverse-transcription real-time PCR, expands the firm's menu of CLIA-waived tests for use in near-patient and point-of-care settings.
The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.
The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.
The test for resistance genes from carbapenemase-producing Gram-negative bacteria can now be used on perirectal swabs and pure colonies.
The test, which received FDA clearance in late 2017, runs in as little as 18 minutes.
The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.
In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
The new instrument has higher throughput than competing systems, while the flu test boasts enhanced sensitivity and protection against seasonal drift.
The Xpert Xpress Flu can detect both influenza A and B virus in 20 minutes from either nasopharyngeal or nasal swabs.
The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.
Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.
Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.
New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.
In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.